Skip to content
MARKETS / NASDAQ / OABI
NASDAQ · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · SMALL CAP

OmniAb, Inc. OABI

5 fiscal years on record · USD · FY2025 reported · SEC filings only
$18.7M
▼ 29.3% YoY
$-64.8M
$-37.0M
In brief

What this company does

We believe the OmniAb animals comprise the most diverse host systems available in the industry. As of December 31, 2025, we had 107 active partners with 407 active programs using the OmniAb technology platform, including 27 OmniAb-derived antibodies in clinical development by our partners, two under regulatory review, and three approved products developed and commercialized by our partners. Our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® have been genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. As part of our efforts to enhance the partner experience, we launched OmniHub™ in December 2024.

Written from the business description in OmniAb, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 4 March 2026. Every sentence was checked against that document before publication.

Growth
USD 18.7M
Revenue, FY2025 · full 5-year series below
Revenue $M Net income $M
FY2025 · Revenue 18.7 · Net income -64.8
20.0M40.0M-25.0M-50.0M20212022202320242025
Compound annual growth
−31.9%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−347 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -369.5% · Net -347.0%
-100%-200%-300%20212022202320242025
ROE
FY2025 · ROE -23.4%
-10%-20%20212022202320242025

Each USD of equity lost 23 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -37.0
-20M-40M20212022202320242025

Total assetsUSD 300.9M
EquityUSD 267.0M
CashUSD 25.5M
Current ratio4.02×

Equity funds 89% of total assets.

The 5-year record
5 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 20252024202320222021
Revenue $B0.00.00.00.10.0
Operating income $B−0.1−0.1−0.1−0.0−0.0
EBITDA $B−0.0−0.1−0.0−0.0−0.0
Income tax $B−0.0−0.0−0.0−0.0−0.0
Net income $B−0.1−0.1−0.1−0.0−0.0
Free cash flow $B−0.0−0.00.0−0.0−0.0
EPS, diluted $−0.57−0.61−0.51−0.26−0.33
Dividend / sh $·····
Payout %·····
ROE %−23.4−20.6−15.4−7.8−11.5
Shares out B0.140.120.120.120.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 21 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 55 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Commercial Physical & Biological Research
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2007

Share this section

Download image